Selected article for: "cellular viral membrane and drug design"

Author: Chew, Miaw-Fang; Poh, Keat-Seong; Poh, Chit-Laa
Title: Peptides as Therapeutic Agents for Dengue Virus
  • Document date: 2017_10_15
  • ID: u1opdwmd_23
    Snippet: In addition, it was observed that many of the antiviral peptides known to inhibit entry of enveloped viruses to cells have hydrophobic and/or amphipathic properties to facilitate the interaction with cellular lipid membrane interfaces [126, 127] . Besides using WWIHS, the interfacial helical hydrophobic moment (iHHM) is another physio-chemical determining strategy which can be used to augment the peptide-membrane interfaces. This approach quantif.....
    Document: In addition, it was observed that many of the antiviral peptides known to inhibit entry of enveloped viruses to cells have hydrophobic and/or amphipathic properties to facilitate the interaction with cellular lipid membrane interfaces [126, 127] . Besides using WWIHS, the interfacial helical hydrophobic moment (iHHM) is another physio-chemical determining strategy which can be used to augment the peptide-membrane interfaces. This approach quantified the segregation of hydrophobic and hydrophilic faces of a peptide folded into an α-helix structure [128] . Higher iHHM value indicates stronger membrane interaction with peptides [129, 130] . Additionally, Badani et al. (2014) also suggested hydrophobicity and amphipathicity to be critical properties for peptides in their interaction with cellular membrane and thereby inhibiting viral entry [126] . Therefore, for future drug design and development, researchers could consider incorporating the hydrophobic and amphipathic properties into antiviral peptides to further enhance antiviral efficacies.

    Search related documents:
    Co phrase search for related documents
    • antiviral efficacy and drug design: 1, 2, 3, 4, 5, 6, 7, 8
    • antiviral efficacy and enveloped virus: 1, 2, 3, 4, 5, 6
    • antiviral efficacy and future drug design: 1
    • antiviral peptide and drug design: 1, 2, 3, 4, 5
    • antiviral peptide and enveloped virus: 1, 2
    • antiviral peptide and future drug design: 1
    • cellular membrane and drug design: 1, 2, 3, 4, 5
    • cellular membrane and enveloped virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • cellular membrane and enveloped virus entry: 1
    • determine strategy and drug design: 1
    • development future drug design and drug design: 1, 2, 3
    • development future drug design and future drug design: 1, 2, 3
    • drug design and enveloped virus: 1, 2, 3
    • drug design and future drug design: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25